Breadcrumb Home News & Events News & Events News April 2022 Announcements The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is delighted to announce the publication of results from IMPAACT P1093 in the May 2022 edition of The Lancet HIV. March 2022 Announcements IMPAACT 2017 (MOCHA) Data Informs U.S. FDA Approval of Cabenuva for HIV Treatment in Virologically Suppressed Adolescents March 2022 Announcements IMPAACT 2014 Informs U.S. FDA’s Approval for Use of Doravirine in Pifeltro® and Delstrigo® Among Children Search Enter a search term. Filter Topics AllAnnouncementsMeetingsStudy Results Date All2022202120202019201820162014 Sort Date AscDate Desc Submit Search Showing 43 news items. January 2021 Announcements IMPAACT MOP Updated January 2021 Announcements IMPAACT at R4P 2021 November 2020 Announcements IMPAACT Award November 2020 Announcements IMPAACT 2007 informs U.S. FDA approval of two supplements September 2020 Meetings Key Dates for CROI 2021 June 2020 Study Results IMPAACT P1093 Informs FDA Decision to Approve First-ever Dolutegravir Dispersible Tablet for Treatment of Children living with HIV June 2020 Announcements Statement from IMPAACT Leadership on Longstanding Racial Injustice March 2020 Meetings COVID-19 Resources March 2020 Study Results IMPAACT 2001 Primary Results Released March 2020 Study Results IMPAACT 2010 Primary Results Released Pagination Previous page Prev Page 1 Page 2 Current page 3 Page 4 Page 5 Next page Next
April 2022 Announcements The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is delighted to announce the publication of results from IMPAACT P1093 in the May 2022 edition of The Lancet HIV.
March 2022 Announcements IMPAACT 2017 (MOCHA) Data Informs U.S. FDA Approval of Cabenuva for HIV Treatment in Virologically Suppressed Adolescents
March 2022 Announcements IMPAACT 2014 Informs U.S. FDA’s Approval for Use of Doravirine in Pifeltro® and Delstrigo® Among Children
June 2020 Study Results IMPAACT P1093 Informs FDA Decision to Approve First-ever Dolutegravir Dispersible Tablet for Treatment of Children living with HIV
